The NIH has announced the appointment of Dr. Gary Gibbons as the new director of the National Heart, Lung, and Blood Institute. Gibbons founded the Cardiovascular Research Institute at the Morehouse School of Medicine and is also its current director. "The globally recognized research and training supported by the NHLBI continues to advance biomedical knowledge in fields related to heart, lung, and blood diseases. I look forward to working with the institute staff and with the many researchers supported by the Institute to foster multidisciplinary approaches to improve disease prevention, diagnosis, and treatment that will advance the health of all Americans," Gibbons said of his appointment.
Donor Recruiting & Retention is About to Get Easier
The donor landscape is changing. According to IDC, by 2015 less than 50% of the U.S. will access the Internet via a desktop computer. Landline phones are virtually obsolete. Get ready for the future of donor recruiting and retention. Learn more.
An analysis of data from the Health and Retirement Study found that elderly people who developed infections after staying in hospitals or nursing homes had a nearly sevenfold higher risk of developing a venous thromboembolism, or clot, while those who developed infections at home had a threefold greater risk of a clot within 90 days. Anemia drugs and blood transfusions also increased an elderly person's risk of a blood clot. The findings appeared online in the journal Circulation.
Researchers at the Children's Hospital of Philadelphia's Center for Cellular and Molecular Therapeutics created a line of human stem cells that may help generate insulin-producing beta cells. The new stem cell line also may serve as a disease-modeling tool to examine how human diseases progress, researchers reported in Cell/Stem Cell.
A drug being developed by Pharmacyclics and Janssen Research and Development shrank or eliminated tumors in 40% of patients with a drug-resistant advanced lymphoma subtype in a small trial, according to a presentation at the American Association for Cancer Research annual meeting. The drug, ibrutinib, blocks the protein Bruton's tyrosine kinase, which National Cancer Institute researchers found to be part of a B-cell-receptor signaling pathway that allows tumor cells to proliferate.
GreatCall introduced this week the subscription-based LiveNurse iPhone application that enables users to connect to a registered nurse any time of the day -- in English or Spanish -- without an appointment. The application, which includes a symptom navigator tool and a medical encyclopedia, has a "Shake for Help" feature that allows users to easily receive information on how a certain screen of the app works.
Oral anemia compound AKB-6548, by Akebia Therapeutics,
achieved the primary objective of increasing hemoglobin
over 42 days during a dose-response midstage test on 93 patients with chronic kidney disease. Akebia said the erythropoietin drug is potentially cheaper and safer than conventional therapy. The firm plans to conduct a six-month Phase IIb trial in the summer.
The Multiple Myeloma Research Foundation is leading a multiyear effort to study whether molecular variations affect patient response to therapy. Scientists at the Van Andel Research Institute in Michigan will collect, store and extract DNA and RNA from tissue samples, and researchers at Spectrum Health will assist with genetic analyses.
OraSure Technologies said the FDA's Blood Products Advisory Committee will review the over-the-counter potential of its OraQuick Rapid HIV-1/2 test on May 15. The company is expected to present consumer-use data at the meeting. "There is an urgent need for additional testing options to identify individuals who are HIV-positive, link them to care and reduce transmission of the virus," OraSure President and CEO Douglas Michels said.
The Senate Health, Education, Labor and Pensions Committee released a discussion draft of a bill to streamline FDA approval of drugs that address life-threatening conditions. Sponsors propose adding the bill to legislation reauthorizing the Prescription Drug User Fee Act.
AABB has made chapters 10 through 17 of the book, "Pathogen Inactivation: The Penultimate Paradigm Shift," available in its Digital Downloads library. Topics include the U.K.'s use of methylene-blue-treated plasma from the U.S., France's use of Cerus Corporation's Intercept platelets and plasma, and the status of pathogen inactivation in the U.S and Europe. Chapters 1 through 9 were previously posted. The chapters are accessible in PDF format, which can be read easily on laptops, iPads, desktops, smartphones and other devices. Visit the AABB Marketplace to purchase this and other AABB Digital Downloads.